Citigroup Issues Positive Forecast for West Pharmaceutical Services (NYSE:WST) Stock Price

West Pharmaceutical Services (NYSE:WST) had its price target upped by analysts at Citigroup from $412.00 to $494.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. Citigroup‘s price objective indicates a potential upside of 19.69% from the company’s current price.

A number of other analysts have also recently commented on WST. UBS Group upped their price objective on West Pharmaceutical Services from $340.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Morgan Stanley raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $365.00 to $400.00 in a research report on Tuesday, September 22nd. Wall Street Zen downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Saturday, October 24th. BNP Paribas Exane initiated coverage on shares of West Pharmaceutical Services in a research report on Monday, July 13th. They set an “outperform” rating and a $447.00 price target for the company. Finally, Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. Twelve equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $409.67.

West Pharmaceutical Services Stock Down 0.9%

WST traded down $3.94 during trading on Friday, hitting $412.73. 1,062,315 shares of the company’s stock traded hands, compared to its average volume of 809,140. The company’s 50 day simple moving average is $366.60 and its two-hundred day simple moving average is $312.50. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a 12-month low of $223.83 and a 12-month high of $438.27. The stock has a market capitalization of $29.05 billion, a price-to-earnings ratio of 52.85, a PEG ratio of 2.83 and a beta of 1.13.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.20 by $0.46. The business had revenue of $874.50 million during the quarter, compared to analyst estimates of $827.12 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.96 EPS. Analysts predict that West Pharmaceutical Services will post 8.92 earnings per share for the current fiscal year.

Insider Activity at West Pharmaceutical Services

In related news, VP Annette Favorite sold 8,135 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $340.81, for a total value of $2,772,489.35. Following the completion of the sale, the vice president directly owned 16,845 shares of the company’s stock, valued at approximately $5,740,944.45. This represents a 32.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold a total of 15,659 shares of company stock valued at $5,443,749 over the last 90 days. 0.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On West Pharmaceutical Services

A number of institutional investors and hedge funds have recently added to or reduced their stakes in WST. Provenance Wealth Advisors LLC boosted its position in West Pharmaceutical Services by 42,650.0% in the 3rd quarter. Provenance Wealth Advisors LLC now owns 855 shares of the medical instruments supplier’s stock valued at $317,000 after buying an additional 853 shares during the period. Integrity Alliance LLC. purchased a new stake in shares of West Pharmaceutical Services in the third quarter valued at approximately $212,000. Aware Super Pty Ltd as trustee of Aware Super purchased a new stake in shares of West Pharmaceutical Services in the third quarter valued at approximately $22,802,000. Bank Julius Baer & Co. Ltd Zurich grew its stake in West Pharmaceutical Services by 39.8% in the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 10,169 shares of the medical instruments supplier’s stock worth $3,791,000 after purchasing an additional 2,893 shares in the last quarter. Finally, Virtue Capital Management LLC grew its stake in West Pharmaceutical Services by 30.5% in the third quarter. Virtue Capital Management LLC now owns 1,009 shares of the medical instruments supplier’s stock worth $374,000 after purchasing an additional 236 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

More West Pharmaceutical Services News

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q3 results exceeded expectations: West reported adjusted earnings of $2.66 per share, above the $2.20 consensus estimate, while revenue rose 8.7% year over year to $874.5 million, surpassing the $827.1 million forecast. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Higher 2026 outlook: Management raised full-year revenue guidance to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion and lifted adjusted EPS guidance to $9.38-$9.48 from $8.85-$9.05. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: Strong high-value product demand: High-Value Product Components sales increased 19.7% and accounted for 53% of quarterly sales, supporting margin expansion and confidence in the company’s growth mix. West Pharma Q3 Earnings Rise on HVP Strength
• Positive Sentiment: Barclays raised its price target to $500 from $440 and maintained an “overweight” rating, implying additional upside based on the referenced share price. Barclays Raises West Pharmaceutical Price Target
• Neutral Sentiment: Institutional positioning was mixed, with several large funds adding shares while others reduced or exited positions. Recent insider activity also showed sales rather than purchases, though these transactions may not reflect the company’s operating outlook.
• Negative Sentiment: Valuation remains a risk after the rally, with the stock trading at a high earnings multiple. One analysis also cautioned that declining cash flow may leave the shares overvalued if earnings growth moderates. West Stock Could Be Overvalued

About West Pharmaceutical Services

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.